23,648 Shares in Enliven Therapeutics, Inc. $ELVN Purchased by Tema Etfs LLC

Key Points

• Tema Etfs LLC has made an investment of approximately $465,000 in Enliven Therapeutics, Inc. during the 1st quarter, acquiring 23,648 shares of the company's stock.
• Enliven Therapeutics reported a quarterly EPS of ($0.49), outperforming analyst expectations of ($0.53).
• Analysts have set a consensus target price of $41.20 for Enliven Therapeutics, with multiple firms giving the stock a Buy rating.

Tema Etfs LLC acquired a new position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 23,648 shares of the company's stock, valued at approximately $465,000.

A number of other large investors have also made changes to their positions in ELVN. Tower Research Capital LLC TRC raised its position in Enliven Therapeutics by 230.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock worth $36,000 after purchasing an additional 1,114 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Enliven Therapeutics by 3,058.1% in the first quarter. GAMMA Investing LLC now owns 2,716 shares of the company's stock worth $53,000 after acquiring an additional 2,630 shares during the last quarter. Quantbot Technologies LP bought a new stake in shares of Enliven Therapeutics during the first quarter worth $60,000. BNP Paribas Financial Markets bought a new stake in shares of Enliven Therapeutics during the fourth quarter worth approximately $112,000. Finally, Brevan Howard Capital Management LP bought a new stake in shares of Enliven Therapeutics during the 4th quarter valued at $228,000. Institutional investors and hedge funds own 95.08% of the company's stock.

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 7,500 shares of the company's stock in a transaction that occurred on Thursday, August 21st. The stock was sold at an average price of $20.01, for a total transaction of $150,075.00. Following the completion of the transaction, the insider owned 940,188 shares of the company's stock, valued at $18,813,161.88. This represents a 0.79% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Anish Patel sold 6,667 shares of the company's stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $18.24, for a total transaction of $121,606.08. Following the completion of the transaction, the chief operating officer owned 289,975 shares of the company's stock, valued at $5,289,144. This trade represents a 2.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 104,234 shares of company stock valued at $2,186,231. Insiders own 25.90% of the company's stock.

Analyst Ratings Changes

ELVN has been the subject of a number of recent analyst reports. Robert W. Baird upped their price objective on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the company an "outperform" rating in a research report on Monday, June 16th. Jones Trading decreased their target price on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a research note on Friday, May 16th. The Goldman Sachs Group initiated coverage on shares of Enliven Therapeutics in a report on Monday, June 16th. They set a "buy" rating and a $37.00 target price for the company. Finally, HC Wainwright boosted their price objective on shares of Enliven Therapeutics from $40.00 to $48.00 and gave the company a "buy" rating in a report on Wednesday, July 2nd. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $41.20.

Enliven Therapeutics Stock Performance

NASDAQ ELVN traded down $0.38 on Wednesday, hitting $20.51. 61,092 shares of the stock traded hands, compared to its average volume of 373,278. Enliven Therapeutics, Inc. has a 12 month low of $13.30 and a 12 month high of $30.03. The business's fifty day moving average is $20.45 and its two-hundred day moving average is $19.78. The firm has a market capitalization of $1.21 billion, a price-to-earnings ratio of -10.24 and a beta of 0.89.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($0.49) EPS for the quarter, topping analysts' consensus estimates of ($0.53) by $0.04. Analysts expect that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.